FDA extends review of weekly LEQEMBI IQLIK for initial Alzheimer's use to Aug. 24, 2026

The U.S. Food and Drug Administration has extended by three months its review of Eisai and Biogen’s bid to use once‑weekly subcutaneous LEQEMBI IQLIK as an initial treatment for early Alzheimer’s disease, moving the Prescription Drug User Fee Act action date to Aug.

24, 2026, the companies said Thursday. Eisai and Biogen said the FDA requested additional information as part of its ongoing review and determined the submission constituted a major amendment, requiring more time to complete the assessment. The companies said the agency has not, at this point, raised concerns about the approvability of LEQEMBI IQLIK for initial treatment.

The application covers a once‑weekly subcutaneous formulation of lecanemab, an anti‑amyloid beta antibody marketed in the United States as LEQEMBI IQLIK. Eisai and Biogen said they believe a comprehensive clinical data package evaluating subcutaneous administration across multiple clinical trials and dosing regimens supports initial‑treatment use.

The extension follows the FDA’s Aug. 26, 2025 approval of a subcutaneous maintenance dosing regimen for LEQEMBI IQLIK. The current filing seeks to expand use of the once‑weekly subcutaneous formulation into initial treatment, following that prior decision. The companies said the therapy has been approved by regulators in more than 50 markets globally as a treatment option for early Alzheimer’s disease.

A subcutaneous option could offer greater flexibility than intravenous infusion, which has been the standard delivery route for anti‑amyloid Alzheimer’s therapies. Lecanemab is among a small group of anti‑amyloid medicines cleared for early Alzheimer’s disease, a class that has drawn close scrutiny from regulators, physicians and payers over clinical benefit, safety monitoring and practical access.

In the United States, use of such drugs typically involves specialist diagnosis and imaging or biomarker confirmation of amyloid pathology. Eisai and Biogen said they will continue discussions with the FDA during the review and are working to make the option available to patients and care partners as quickly as possible.

According to the companies, Eisai leads global development and regulatory submissions for lecanemab, while Eisai and Biogen co‑commercialize and co‑promote the medicine under Eisai’s final decision‑making authority. The partners have collaborated on Alzheimer’s therapies since 2014.

If approved, the initial‑treatment label expansion for LEQEMBI IQLIK would mark another step toward more convenient administration formats for lecanemab. The extended review, however, pushes back the expected decision, leaving physicians, patients and investors awaiting regulatory clarity until late August.